Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2019 /
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma

27th Sep - 1st Oct 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.10.19
Views: 453

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain

Dr Ana Arance speaks to ecancer at ESMO 2019 in Barcelona about the Checkmate 067 trial.

This trial looks at nivolumab plus ipilimumab combination therapy in advanced melanoma, and at ESMO 2019 we saw the 5 year survival outcomes.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation